1 week Ago By Defense World Staff
Sei Investments Co. trimmed its holdings in shares of Viking Therapeutics, Inc. ( NASDAQ:VKTX – Free Report ) by 41.
9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 21,451 shares of the biotechnology company’s stock after selling 15,486 shares during the period. Sei Investments Co.
’s holdings in Viking Therapeutics were worth $863,000 at the end of the most recent quarter. Other institutional investors also recently modified their holdings of the company. S.
A. Mason LLC grew its stake in shares of Viking Therapeutics by 20.0% during the 4th quarter.
S.A. Mason LLC now owns 1,800 shares of the biotechnology company’s stock valued at $72,000 after purchasing an additional 300 shares during the period.
Blue Trust Inc. increased its holdings in Viking Therapeutics by 75.9% in the 4th quarter.
Blue Trust Inc. now owns 716 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 309 shares during the last quarter. Bank Julius Baer & Co.
Ltd Zurich lifted its stake in Viking Therapeutics by 7.4% in the 4th quarter. Bank Julius Baer & Co.
Ltd Zurich now owns 4,980 shares of the biotechnology company’s stock worth $221,000 after purchasing an additional 345 shares in the last quarter. Arizona State Retirement System increased its holdings in shares of Viking Therapeutics by 1.2% in the fourth quarter.
Arizona State Retirement System now owns 28,929 shares of the biotechnology company’s stock worth $1,164,000 after purchasing an additional 353 shares during the last quarter. Finally, Activest Wealth Management raised its holdings in shares of Viking Therapeutics by 24.1% during the 4th quarter.
Activest Wealth Management now owns 2,165 shares of the biotechnology company’s stock worth $87,000 after acquiring an additional 420 shares in the last quarter. 76.03% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth Several research firms have recently issued reports on VKTX. The Goldman Sachs Group initiated coverage on Viking Therapeutics in a research note on Tuesday. They issued a “neutral” rating and a $30.
00 price objective for the company. Scotiabank began coverage on shares of Viking Therapeutics in a report on Thursday, February 13th. They set a “sector outperform” rating and a $102.
00 price objective on the stock. B. Riley reiterated a “buy” rating and issued a $96.
00 target price (down previously from $109.00) on shares of Viking Therapeutics in a research note on Friday, February 7th. HC Wainwright restated a “buy” rating and issued a $102.
00 price target on shares of Viking Therapeutics in a report on Wednesday, March 26th. Finally, Piper Sandler decreased their price objective on Viking Therapeutics from $74.00 to $71.
00 and set an “overweight” rating for the company in a report on Thursday, February 6th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Viking Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $89.
75. Viking Therapeutics Stock Down 6.1 % Viking Therapeutics stock opened at $19.
98 on Wednesday. The business’s 50-day moving average price is $28.52 and its 200 day moving average price is $44.
21. Viking Therapeutics, Inc. has a 52 week low of $19.
58 and a 52 week high of $81.86. The firm has a market cap of $2.
24 billion, a price-to-earnings ratio of -19.98 and a beta of 0.84.
Viking Therapeutics ( NASDAQ:VKTX – Get Free Report ) last released its quarterly earnings results on Wednesday, February 5th. The biotechnology company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.
27) by ($0.05). During the same period in the prior year, the business earned ($0.
25) earnings per share. Equities analysts expect that Viking Therapeutics, Inc. will post -1.
56 EPS for the current year. Insiders Place Their Bets In other news, Director Sarah Kathryn Rouan bought 1,240 shares of the firm’s stock in a transaction dated Monday, March 31st. The shares were acquired at an average price of $24.
15 per share, for a total transaction of $29,946.00. Following the completion of the transaction, the director now directly owns 1,240 shares in the company, valued at $29,946.
The trade was a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link . 4.
70% of the stock is currently owned by company insiders. Viking Therapeutics Profile ( Free Report ) Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Featured Stories Five stocks we like better than Viking Therapeutics Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance Tariff-Proof Stocks: 3 Big Bargains With Huge Upside Potential Election Stocks: How Elections Affect the Stock Market Qualcomm Breaks Down But RSI Signals It’s Severely Oversold What is Forex and How Does it Work? Tesla’s #1 Bull Cuts Target But Says It’s Still a Buy Want to see what other hedge funds are holding VKTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Viking Therapeutics, Inc. ( NASDAQ:VKTX – Free Report ).
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter ..
